Tech

Apple Scores Key Win as ITC Rejection Keeps Watch Imports Flowing

Apple scored a regulatory win after the ITC declined to revisit its prior finding that allowed Watch imports to continue. Masimo’s bid to reinstate an import ban was denied, preserving Apple’s ability to sell newer Apple Watch models with health-sensor features.

📅 April 18, 2026
⏱️ 2 min read
Apple Scores Key Win as ITC Rejection Keeps Watch Imports Flowing

Key Takeaways

  • The ITC declined to revisit its ruling, denying Masimo’s bid to reinstate the import ban.
  • Apple Watch imports can continue; Apple redesigned models to move blood-oxygen data to paired devices following the 2023 ruling.
  • Masimo remains in litigation, pursuing appeals and facing a separate $634 million California verdict against Apple.
  • Apple stock traded around $270 in mid-April 2026 (close $270.23, +2.59%; after-hours $270.75) and Masimo around $178.39.

People Involved

  • No specific individuals mentioned

Entities Involved

  • Apple Inc. (AAPL) Technology company
  • Masimo Corp. (MASI) Medical technology company

MarketMoodz Analysis

For investors, the ITC’s rejection of Masimo’s bid reduces near-term regulatory risk to Apple’s watch supply chain and product lineup, supporting hardware sales and potential margin stability as wearables remain a growth pillar. The ruling also clarifies IP positioning in a high-stakes health-sensor space, potentially shaping future licensing dynamics and litigation playbooks among rivals.

Historically, the 2023 ITC finding blocked imports of certain Apple Watch models tied to Masimo’s blood-oxygen technology. Apple’s design response—shifting health data display to paired devices—helped preserve access to the core product line while potentially setting a precedent for how hardware IP disputes are resolved in consumer devices. Looking ahead, Masimo’s appeals, other ITC actions affecting wearables, and Apple’s upcoming guidance on wearables and component supply will be critical to watch.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial